4.5 Review

A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy

Journal

VACCINE
Volume 41, Issue 13, Pages 2101-2112

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2023.02.032

Keywords

Coronavirus; Pandemic preparedness; COVID-19 vaccines; Coronavirus vaccines; Broadly protective coronavirus vaccines; Roadmap; Vaccine research

Ask authors/readers for more resources

Broadly protective coronavirus vaccines are crucial for future protection from SARS-CoV-2 variants and future outbreaks caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap aims to promote their development. It is funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation and involves collaboration with international experts. The roadmap outlines major research areas, milestones, and priorities for funding and research campaigns.
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high -priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available